基于Affibody的肽核酸介导预靶向策略对表达HER2的人源异种移植瘤进行放射性核素治疗:体内原理验证
研究采用靶向HER2的Affibody分子偶联PNA杂交探针(ZHER2:342-SR-HP1)作为预靶向剂,以177Lu标记的互补PNA(177Lu-HP2)为次级剂,在SKOV-3异种移植小鼠中行6个周期(间隔7天)的预靶向放射性核素治疗。结果显示治疗组小鼠生存期(66天)显著长于各对照组(32-37天,P<0.05),且肿瘤吸收剂量为1075 mGy/MBq,肾脏为206 mGy/MBq、血液为4 mGy/MBq。
要点
- 预靶向方案:注射100 μg ZHER2:342-SR-HP1后16小时,给予16 MBq/3.5 μg 177Lu-HP2。
- 肿瘤吸收剂量1075 mGy/MBq,肾脏206 mGy/MBq,血液4 mGy/MBq。
- 治疗组生存期66天,显著长于各对照组(32-37天,P<0.05)。
核心结论
- 所研究的预靶向系统可向肿瘤递送明显超过关键器官的吸收剂量,使基于Affibody的PNA介导预靶向放射性核素治疗极具吸引力。
研究设计与样本
- 在荷SKOV-3异种移植瘤小鼠中行实验性放射性核素治疗,共6个周期,周期间隔7天。
- 预靶向剂为靶向HER2的Affibody分子连接AGTCGTGATGTAGTC PNA杂交探针(ZHER2:342-SR-HP1)。
- 次级剂为互补AGTCGTGATGTAGTC PNA偶联DOTA螯合剂并标记177Lu(177Lu-HP2)。
主要发现
- 最佳肿瘤靶向在注射100 μg(7.7 nmol)ZHER2:342-SR-HP1后16小时注射16 MBq/3.5 μg(0.65 nmol)177Lu-HP2时获得。
- 计算肿瘤吸收剂量为1075 mGy/MBq,肾脏为206 mGy/MBq,血液(骨髓替代)为4 mGy/MBq。
- 治疗组生存期为66天,显著长于仅用同量ZHER2:342-SR-HP1组(37天)、仅用同量同活度177Lu-HP2组(32天)及磷酸盐缓冲液组(37天)(P<0.05)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Affibody molecules are small proteins engineered using a nonantibody scaffold. Radiolabeled Affibody molecules are excellent imaging probes, but their application to radionuclide therapy has been prevented by high renal reabsorption. The aim of this study was to test the hypothesis that Affibody-based peptide nucleic acid (PNA)-mediated pretargeted therapy of human epidermal growth factor receptor 2 (HER2)-expressing cancer extends survival without accompanying renal toxicity. Methods: A HER2-targeting Affibody molecule ligated with an AGTCGTGATGTAGTC PNA hybridization probe (ZHER2:342-SR-HP1) was used as the primary pretargeting agent. A complementary AGTCGTGATGTAGTC PNA conjugated to the chelator DOTA and labeled with the radionuclide 177Lu (177Lu-HP2) was used as the secondary agent. The influence of different factors on pretargeting was investigated. Experimental radionuclide therapy in mice bearing SKOV-3 xenografts was performed in 6 cycles separated by 7 d. Results: Optimal tumor targeting was achieved when 16 MBq/3.5 μg (0.65 nmol) of 177Lu-HP2 was injected 16 h after injection of 100 μg (7.7 nmol) of ZHER2:342-SR-HP1. The calculated absorbed dose to tumors was 1,075 mGy/MBq, whereas the absorbed dose to kidneys was 206 mGy/MBq and the absorbed dose to blood (surrogate of bone marrow) was 4 mGy/MBq. Survival of mice was significantly longer (P < 0.05) in the treatment group (66 d) than in the control groups treated with the same amount of ZHER2:342-SR-HP1 only (37 d), the same amount and activity of 177Lu-HP2 only (32 d), or phosphate-buffered saline (37 d). Conclusion: The studied pretargeting system can deliver an absorbed dose to tumors appreciably exceeding absorbed doses to critical organs, making Affibody-based PNA-mediated pretargeted radionuclide therapy highly attractive.
引用
- Westerlund K, Altai M, Mitran B, et al. Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting: In Vivo Proof of Principle. J Nucl Med. 2018. PMID: 29439013. doi:10.2967/jnumed.118.208348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。